5-Fluorouracil-β-Cyclodextrin conjugates:Linker strategies to enhance the anticancer efficacy and reduce the side effects
5-Fluorouracil (5-FU) serves as a first-line therapeutic agent for colorectal cancer, however, its utility is limited by a short half-life and significant cytotoxicity. This study focused on the construction of 5-Fluorouracil-β-Cyclodextrin polymers (5-FUSA-β-CD and 5-FUBA-β-CD) by covalent conjugat...
Saved in:
Main Authors: | Liangliang Hu, Ting Meng, Davies Marabada, Zhichao Jin, Qing Huang, Shijie Wei, Zhizhong Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-03-01
|
Series: | Carbohydrate Polymer Technologies and Applications |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666893925000301 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Optimizing ibrutinib bioavailability: Formulation and assessment of hydroxypropyl-β-cyclodextrin-based nanosponge delivery systems
by: Sunitha Sampathi, et al.
Published: (2025-01-01) -
Exploring the efficacy of fluorouracil and platinum based chemotherapy in advanced hepatocellular carcinoma to bridge the treatment gap in resource limited settings
by: Se Jun Park, et al.
Published: (2025-01-01) -
Enhanced antitumor efficacy through sustained release of 5-fluorouracil from poly(trimethylene carbonate) membranes
by: Zongheng Wang, et al.
Published: (2025-01-01) -
Cyclodextrins’ Internal Cavity Hydration: Insights from Theory and Experiment
by: Silvia Angelova, et al.
Published: (2025-01-01) -
Unlocking Dabrafenib’s Potential: A Quality by Design (QBD) Journey to Enhance Permeation and Oral Bioavailability through Nanosponge Formulation
by: Konda Sri Chaya Reddy, et al.
Published: (2025-01-01)